866-997-4948(US-Canada Toll Free)

T-Cell Leukemia - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 74 Pages


Global Markets Directs, \'T-Cell Leukemia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Leukemia. 

T-Cell Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for T-Cell Leukemia.
  • A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the T-Cell Leukemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
T-Cell Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for T-Cell Leukemia 8
T-Cell Leukemia Therapeutics under Development by Companies 10
T-Cell Leukemia Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
T-Cell Leukemia Therapeutics - Products under Development by Companies 16
T-Cell Leukemia Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in T-Cell Leukemia Therapeutics Development 18
Bristol-Myers Squibb Company 18
Kyowa Hakko Kirin Co., Ltd. 19
Merck & Co., Inc. 20
Novartis AG 21
Pfizer Inc. 22
Enzon Pharmaceuticals, Inc. 23
Celgene Corporation 24
Mundipharma International Limited 25
Pharmacyclics, Inc. 26
Stemline Therapeutics, Inc. 27
CytImmune Sciences, Inc. 28
T-Cell Leukemia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
MK-4827 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
panobinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ENZ-3042 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mogamulizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PCI-34051 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
forodesine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SL-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Mik-Beta-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PF-03084014 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lenalidomide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ibrutinib + [ofatumumab] - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BMS-906024 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peripheral Blood Stem Cell Transplantation - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
IMTOX-25 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
mogamulizumab + mLSG15 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 57
lenaldekar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CYT-91000 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
T-Cell Leukemia Therapeutics - Drug Profile Updates 61
T-Cell Leukemia Therapeutics - Dormant Products 69
T-Cell Leukemia - Product Development Milestones 70
Featured News & Press Releases 70
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 70
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 70
Apr 09, 2012: Study Demonstrates Potential Of New Anti-Leukemia Compound, Lenaldekar 70
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 71
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 72

Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Table


Number of Products Under Development for T-Cell Leukemia, H1 2013 8
Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
Bristol-Myers Squibb Company, H1 2013 18
Kyowa Hakko Kirin Co., Ltd., H1 2013 19
Merck & Co., Inc., H1 2013 20
Novartis AG, H1 2013 21
Pfizer Inc., H1 2013 22
Enzon Pharmaceuticals, Inc., H1 2013 23
Celgene Corporation, H1 2013 24
Mundipharma International Limited, H1 2013 25
Pharmacyclics, Inc., H1 2013 26
Stemline Therapeutics, Inc., H1 2013 27
CytImmune Sciences, Inc., H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 34
T-Cell Leukemia Therapeutics - Drug Profile Updates 61
T-Cell Leukemia Therapeutics - Dormant Products 69

List of Chart


Number of Products under Development for T-Cell Leukemia, H1 2013 8
Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Discovery and Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Route of Administration, H1 2013 31
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Molecule Type, H1 2013 33
Assessment by Stage and Molecule Type, H1 2013 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *